Gene Therapy Trial Doses First DMD Patient – Rare Disease Report
Rare Disease Report |
Gene Therapy Trial Doses First DMD Patient
Rare Disease Report … create a brighter future for these children," said Douglas Ingram, Sarepta's president and chief executive officer. "Sarepta is the world leader in precision genetic medicine to treat DMD, spanning RNA-targeted therapies, gene therapy, and gene … |
